Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

UK's FTSE 100 drifts to record high in thin year-end trade London's FTSE 100 index hit a record high in quiet trading on Tuesday, the penultimate session of 2025, supported by gains in banks and ...